MEI Pharma
Committed to the development of novel, best-in-class, cancer therapies intended to provide improved outcomes to patients
121 employees · est. 2000 · San Diego, United States
Prelude Therapeutics
Precision Oncology, Redefined.
126 employees · est. 2016 · Wilmington, United States
MEI Pharma is the older company (2000 vs 2016).
Side-by-Side Comparison
| Metric | MEI Pharma | Prelude Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2000 older | 2016 |
| Headquarters | ||
| Headquarters | San Diego, United States | Wilmington, United States |
| Employees | ||
| Employees | 121 | 126 |
| Industry | ||
| Industry | Biopharma, Biotechnology | Biopharma, Biotechnology, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $160.36M | $147.00M |
| Funding Rounds | ||
| Funding Rounds | 5 | 4 |
| Services | ||
| Services | Not tracked yet | Development of precision oncology medicines, Innovative cancer drug discovery, Targeted protein degradation technology, Pipeline of clinical and preclinical programs |
| Target Customers | ||
| Target Customers | Not tracked yet | Cancer Patients, Oncologists, Healthcare Providers, Pharmaceutical Partners |
| Taxonomy | ||
| Taxonomy | Oncology Company, Clinical-stage Pharmaceutical Company, Novel Cancer Therapies, B-cell Malignancies, Hematologic Malignancies, Solid Tumors, Drug Development, Clinical Trials, HDAC Inhibitor, Histone Deacetylase Inhibitor, Mitochondrial Inhibitor, CDK9 Inhibitor, ME-401, Pracinostat, ME-344 | Precision Oncology, Clinical-stage, Cancer Therapeutics, Small Molecule Compounds, Targeted Cancer Pathways, SMARCA2 Degrader, CDK9 Inhibitor, CDK4/6 Inhibitor, Cancer Resistance Mechanisms, Oncology Drug Development, Orally Bioavailable Therapies, Novel Cancer Therapies, Healthcare Innovation, Cancer Research |
| Website | ||
| Website | meipharma.com | preludetx.com |
About MEI Pharma
MEI Pharma, a San Diego-based clinical-stage pharmaceutical company, is dedicated to developing and commercializing novel, best-in-class cancer therapies with the aim of improving patient outcomes. The company's approach involves understanding and leveraging the mechanisms and properties of its drug...
About Prelude Therapeutics
Prelude Therapeutics, founded in 2016, is a United States-based clinical-stage precision oncology company redefining cancer treatment with a focus on developing innovative drug candidates that target critical cancer cell pathways. The company uniquely positions itself within the Biopharma, Biotechno...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at MEI Pharma and Prelude Therapeutics — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at MEI Pharma and Prelude Therapeutics — by email.
Frequently Asked Questions
Compare MEI Pharma with someone else
Start typing a company name or domain.